Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix(Hospital Clínic de Barcelona), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Guido Gerken, Camillo Porta(University of Pavia), Angelo Sangiovanni(Ospedale Maggiore), D. Voliotis(Bayer (United States)), Andrea Nadel(Bayer (United States)), Morris Sherman(University Health Network), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Peter R. Galle(Johannes Gutenberg University Mainz), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Antonio Craxı̀(University of Palermo), Armando Santoro(IRCCS Humanitas Research Hospital), Michel Beaugrand(Hôpital Jean-Verdier), Michael Shan(Bayer (United States)), M. Moscovici(Bayer (Italy)), Luigi Bolondi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Jorge A. Marrero(University of Pennsylvania)
Cited by 821
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.1k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k